HER-2/neu overexpression in breast cancer: An immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D

Anticancer Research

Volumn 21, Issue 3 C, 2001, Pages 2207-2212

  Korkolis, D ^a   Ardavanis, A ^a   Yotis, J ^a   Kyroudi, A ^a   Gorgoulis, V ^a   Kittas, C ^a  

^a NONE   (Greece)

Author keywords

Breast cancer; Cathepsin D; HER 2 neu; P53; Prognostic factors

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; ONCOPROTEIN; PARAFFIN; POLYCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CATHEPSIN D; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034898408     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2
2. The HER-2/neu oncogene in breast cancer: Prognostic factor, Predictive factor and target for therapy
3. Histological grading and prognosis in breast cancer
4. Prognostic significance of c-erbB-2 expression in node negative breast cancer
5. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node negative breast carcinomas
6. Quantitative analysis of p185 (HER-2/neu) protein in breast cancer and its association with other prognostic factors
7. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
8. Immunohistochemical localization of c-erbB-2, in human breast carcinomas
9. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogence c-erbB-2 in mammary tumor lines
10. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
11. HER-2/neu oncogene protein and prognosis in breast cancer
12. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma
13. c-erbB-2 positive breast tumors behave more aggressively in the first years after diagnosis
14. Immunohistochemical expression of p53 and c-erbB-2 proteins in breast cancer in Egypt
15. c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasis
16. HER-2/neu node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
17. Optimization of immunohistochemical detection of c-erbB-2 in human breast cancer: Impact of fixation
18. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers and clinical stage in human breast cancer
19. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
20. Prospective studies of p53 and c-erbB-2 expression relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement
21. Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer
22. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
23. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer
24. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer
25. Immunohistochemical detection of HER-2/neu in patients with axillary lymph node negative breast carcinoma
26. ERBB2 amplification in breast cancer with high rate of proliferation
27. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors
28. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer
29. Follow-up study of HER-2/neu amplification in primary breast cancer
30. Prognostic value of Cathepsin-D expression and association with histomorphological subtypes in breast cancer
31. c-erbB-2 oncogene protein in in situ and invasive lobular breast carcinoma
32. The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma
33. Cathepsin-D and c-erbB-2 have an additive prognostic value for breast cancer patients
34. Cathepsin-D assay in primary breast cancer and lymph nodes: Relationship with c-myc, c-erbB-2 and int-2. Oncogene Amplification and node invasiveness
35. Cathepsin-D in primary, breast cancer: Prognostic evaluation involving 2810 patients
36. Transferred cathepsin-D stimulates high density cancer cell growth by inactivating secreted growth inibitors
37. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer
38. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer
39. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR and steroid hormone receptors for short term prognosis in breast cancer
40. Correlation between p53, c-erbB-2 and topoisomerase IIa expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications
41. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation
42. Prognostic value of p53 expression in early stage breast carcinoma compared with tumor angiogenesis, epidermal growth factor receptor, c-erbB-2, cathepsin-D, ploidy, parameters of cell kinetics and conventional features
43. p53 oncoprotein as a prognostic indicator in patients with breast cancer
44. Matrix metalloproteinase 3 expression in human breast cancer: An immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fobronectin, EGFR, C-erbB-2 oncoprotein p53, steroid receptors, status and proliferative indices